# Repligen Corporation – Consensus ‘buy’ rating and 40.6% Upside Potential

- Link: https://www.directorstalkinterviews.com/repligen-corporation-consensus-buy-rating-and-40.6-upside-potential/4121130839
- Published: 2023-10-26T12:33:05+01:00
- Author: Charlotte Edwards

**Repligen Corporation** which can be found using ticker (RGEN) have now 13 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The target price High/Low ranges between 240 and 165 suggesting an average Analsyt
target price of $196.54. Given that the stocks previous close was at $139.78 and
the analysts are correct then we can expect a percentage increase in value of 40.6%.
The 50 day MA is $158.83 and the 200 moving average now moves to $165.90. The total
market capitalization for the company now stands at 6.94B. The current share price
for the company is: 124.42 USD

 The potential market cap would be $9,754,163,766 based on the market consensus.

The company has a dividend yield of 5.38%. Other points of data to note are a P/
E ratio of 51.63, revenue per share of 13.12 and a 3.46% return on assets.

Repligen Corporation is a life sciences company, which develops and commercializes
bioprocessing technologies and systems that rises flexibility in the process of 
manufacturing biological drugs. The Company’s bioprocessing business consist of 
four franchises, filtration; chromatography; process analytics; and proteins. The
Filtration products are used in process development and process scale production.
The Chromatography franchise includes products used in downstream purification, 
development, and manufacturing of biological drugs. The Process Analytics products
allow end-users to make in-line absorbance measurements allowing for the determination
of protein concentration in filtration, chromatography formulation and fill-finish
applications. The Proteins franchise is represented by its Protein A affinity ligands,
which are a critical component of Protein A chromatography resins used in downstream
purification of virtually all monoclonal antibody (mAb) based drugs on the market.

Share on: